Launch Therapeutics (Launch Tx) has chosen Medidata’s AI Intelligent Trials solution to accelerate clinical trials of late-stage therapies.

Launch Tx will use Medidata AI Intelligent Trials’ study feasibility solution for trial planning, further improving enrolment and quality.

The solution provides country and site-level performance data and predictive analytics from more than 30,000 clinical trials of various diseases representing over nine million study participants.

Launch Tx Clinical Operations executive vice-president Elisha Talley-Roithner said: “Medidata brings expertise, industry leading data, and insights. We are proud to partner with this global leader to help bring fresh approaches to facilitate drug development.

“Our industry partners can trust that through our work with Medidata, we are committed to finding solutions that address key industry challenges and advance study timelines.”

The clinical trial analytics solution from Medidata brings together predictive models, cross-industry real-time performance metrics, along with forecasting capabilities for offering a competitive edge in planning and execution of clinical trials.

Medidata AI head Fareed Melhem said: “Launch Tx is taking an exciting approach to investing in and driving clinical trial development.

“Adding unique insights from our Intelligent Trials solution will support their mission to disrupt the late-stage development paradigm.”

Last December, Medidata unveiled a new patient-centric native myMedidata app to accelerate the start up of clinical trials and enhance patient experience.

Worldwide, more than 1,700 customers and partners are using Medidata’s platform for clinical development and to access commercial, and real-world data.